Search
Qiagen NV
QGENAdd to Watchlist
41.400USD
-0.050-0.12%
Close 07-31 16:00（ET）Quotes delayed by 15 min
8.54BMarket Cap
22.15P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Qiagen NV is 7.25, ranking 304 out of 385 in the Biotechnology & Medical Research industry. The average price target is 50.00, with a high of 57.00 and a low of 45.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
45.098
Target Price
+7.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Qiagen NV
QGEN
16
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Qiagen NV's expected revenue for the next quarter?
Qiagen NV's expected revenue is 527.48M.
What is Qiagen NV's price target?
Analysts forecast that Qiagen NV's price target is USD 50.00, with the highest forecast at USD 57.00 and the lowest forecast at USD 45.00.
How have Qiagen NVQGEN's recent earnings per share performed?
The market expectation was USD 0.33, while Qiagen NVQGEN's earnings per share (EPS) for the previous quarter was USD 0.50. EPS for the next quarter is expected at USD 0.60.
What is the analyst rating for Qiagen NV?
Based on the ratings of Qiagen NV's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.